Study record
TA-65 and immune / telomere markers in a health-maintenance program (Harley et al., 2011)
Human — telomerase-activator biomarker study (commercial program)
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
○ Evidence tier 3 — Human RCT — telomere-length / telomerase-activity biomarker endpoint
Record
| Design | Non-randomized biomarker evaluation within a commercial health-maintenance program |
| DOI | 10.1089/rej.2010.1085 |
| Citation status | doi cross-confirmed via Crossref reference lists 2026-07-12 (Rejuvenation Res 2011;14(1):45-56, Harley et al., 'A Natural Product Telomerase Activator As Part of a Health Maintenance Program'); cited in Bernardes de Jesus 2012 (ref CR32) and Salvador 2016 (ref 1). COMMERCIAL COI: T.A. Sciences authorship. PMID not separately fetched (DOI cross-confirmed as the primary identifier). |
Five-qualifier claim
| Species / population | Older adults enrolled in a commercial health-maintenance program (TA-65 evaluated with a range of biomarkers). |
| Exposure, route, schedule | Oral TA-65 as part of a supplement/health-maintenance program. |
| Comparator / duration | Non-randomized program evaluation with biomarker follow-up. |
| Endpoint / numeric result | Reported a decline in the proportion of senescent (CD8+CD28−) cytotoxic T cells and lengthening of the shortest telomeres — immune and telomere biomarker signals. |
| What it did NOT establish | Biomarker endpoints in a commercial program, not a controlled clinical outcome. Strong commercial conflict of interest; no healthy-aging or lifespan benefit is established. |
Interventions
Primary reference
https://doi.org/10.1089/rej.2010.1085
Exact identifier confirmed against the primary record via Crossref/ClinicalTrials.gov where stated in the citation status; anything marked needs_primary_fulltext is not yet confirmed.